26 results
6-K
EX-99.1
GRCL
Gracell Biotechnologies Inc
17 Jan 24
Current report (foreign)
4:30pm
Company until their successors are duly elected and qualified or until such director’s earlier death, resignation or removal. At the Effective Time … elected and qualified or until such director’s earlier death, resignation or removal. At the Effective Time, the memorandum and articles
6-K
EX-99.1
GRCL
Gracell Biotechnologies Inc
26 Dec 23
Voting and Support Agreement
8:12am
the death of the Shareholder; provided that, as a condition to any such Transfer pursuant to the foregoing clauses (i) and (ii), the recipient agrees
6-K
EX-2.1
GRCL
Gracell Biotechnologies Inc
26 Dec 23
Voting and Support Agreement
8:12am
elected and qualified or until such director’s earlier death, resignation or removal.
(b) The officers of Merger Sub immediately prior … are duly elected and qualified or until such officer’s earlier death, resignation or removal.
-3-
Article II
EFFECT OF MERGER ON ISSUED SHARE
6-K
EX-99.2
GRCL
Gracell Biotechnologies Inc
7 Aug 23
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
8:07am
, resulting in serious morbidity and even death SLE affects over three million people1 worldwide, with disproportionate burden of disease seen among young … PR ◼ CR/CRi Allo-HSCT In Follow-up Death
Allogeneic CAR-T from HLA-Matched Donor GC007g for B-ALL CD19 DONOR-DERIVED CAR
30 Allo-HSCT, allogeneic
6-K
EX-99.1
GRCL
Gracell Biotechnologies Inc
16 May 23
Gracell announces start of investigator-initiated trial to expand clinical evaluation of FasTCAR-T GC012F into autoimmune disease
4:00pm
of life, and has no cure. Furthermore, refractory/severe SLE could lead to permanent organ damage, resulting in serious morbidity and even death
20-F
EX-4.27
7fxaq3plok33jynnm
23 Apr 21
Annual report (foreign)
4:04pm
20-F
EX-4.28
3wrmsoxv j78zu2c
23 Apr 21
Annual report (foreign)
4:04pm
20-F
ix5kll
23 Apr 21
Annual report (foreign)
4:04pm
6-K
EX-99.2
7qlwku7
6 Apr 21
The collaboration will help Gracell leverage Lonza’s worldwide integrated services and expertise in CAR-T cell therapy manufacturing
4:02pm
424B4
oypmsrv 1vcdh
8 Jan 21
Prospectus supplement with pricing info
1:42pm
F-1/A
fyc2w2 ae
7 Jan 21
Registration statement (foreign) (amended)
7:03am
F-1/A
mswp0i
6 Jan 21
Registration statement (foreign) (amended)
12:00am
F-1/A
nf3kth5j 7e
4 Jan 21
Registration statement (foreign) (amended)
9:30am
F-1
EX-3.1
m8vu068wax5mqzjbo5
18 Dec 20
Registration statement (foreign)
4:18pm
F-1
EX-3.2
ijh4tweu8vxv9v3rng8x
18 Dec 20
Registration statement (foreign)
4:18pm
F-1
EX-10.2
zviz49k y8jv
18 Dec 20
Registration statement (foreign)
4:18pm
F-1
j18qn4
18 Dec 20
Registration statement (foreign)
4:18pm